Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556780 | 0.88 | ALDH1A1 (0.42) | SMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL2521674 | 0.87 | HDAC3 (0.40) | SMN1; SMN2DPP4DPP7ALDH1A1L3MBTL1 | |
| SCHEMBL3566688 | 0.81 | LMNA (0.37) | MAPT | |
| SCHEMBL3561802 | 0.77 | LMNA (0.35) | — | |
| Brivaracetam SCHEMBL2408675 | 0.76 | CA1 (0.49) | MAPTALDH1A1 | |
| Brivaracetam SCHEMBL563970 | 0.76 | CA1 (0.49) | MAPTALDH1A1 | |
| Brivaracetam SCHEMBL564055 | 0.76 | CA1 (0.49) | MAPTALDH1A1 | |
| Brivaracetam SCHEMBL22446812 | 0.76 | CA1 (0.49) | MAPTALDH1A1 | |
| Brivaracetam SCHEMBL563380 | 0.76 | CA1 (0.49) | MAPTALDH1A1 | |
| Brivaracetam SCHEMBL122081 | 0.76 | CA1 (0.49) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7692028-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-04-06 | — | — | US | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | EPHX1 274/4885GAA 609/4885PPARG 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.